0001193125-14-126013.txt : 20140401 0001193125-14-126013.hdr.sgml : 20140401 20140401162110 ACCESSION NUMBER: 0001193125-14-126013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140401 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140401 DATE AS OF CHANGE: 20140401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DURECT CORP CENTRAL INDEX KEY: 0001082038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943297098 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31615 FILM NUMBER: 14734479 BUSINESS ADDRESS: STREET 1: 10240 BUBB RD CITY: CUPERTINO STATE: CA ZIP: 95014 BUSINESS PHONE: 4087771417 MAIL ADDRESS: STREET 1: 10240 BUBB ROAD CITY: CUPERTINO STATE: CA ZIP: 95014 8-K 1 d704733d8k.htm FORM 8-K Form 8-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

April 1, 2014

Date of Report

(Date of earliest event reported)

 

 

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware
  000-31615   94-3297098

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

10260 Bubb Road

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On April 1, 2014, DURECT Corporation, a Delaware corporation (“DURECT”), issued a press release announcing POSIDUR™ (SABER®-Bupivacaine) data presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. A copy of DURECT’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

 

99.1    Press Release of DURECT Corporation dated April 1, 2014


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    DURECT Corporation
Date: April 1, 2014     By:  

/s/ Matthew J. Hogan

      Matthew J. Hogan
      Chief Financial Officer


DURECT CORPORATION

INDEX TO EXHIBITS

 

Exhibit
Number

  

Description

99.1    Press Release of DURECT Corporation dated April 1, 2014
EX-99.1 2 d704733dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting

CUPERTINO, CA, April 1, 2014 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago.

“We’re pleased to have this presence at ASRA as part of our on-going effort to communicate to the medical community data that we have generated in our development program for POSIDUR,” stated James E. Brown, President and CEO of DURECT Corporation.

Abstract information and authors for the following posters that will be presented on Saturday, April 5, 2014 at 9:30-11:00 a.m.:

Presentation Title: Efficacy and Safety of SABER®-Bupivacaine Local Anesthetic in Open Hernia Repair

Authors: Dr. Richard Watts (The Queen Elizabeth Hospital, Department of Anaesthesia, Woodville, South Australia, Australia), Dr. Dave Ellis and Dr. Neil Verity (DURECT Corporation, Cupertino, CA), Dr. Alex Yang (Xelay Acumen, Belmont, CA), Dr. Richard Turner (University of Tasmania School of Medicine, Hobart, Tasmania, Australia)

Presentation Title: Treatment of Postoperative Pain in Shoulder Surgery with SABER®-Bupivacaine

Authors: Dr. Anders Ekelund (Department of Orthopaedics, Capio St. Gorans Hospital, Stockholm, Sweden), Dr. Andrejs Peredistijs (Department of Orthopaedics, Clinic of Traumatology and Orthopaedics, Riga, Latvia), Dr. Josef Grohs (Department of Orthopaedics, Medical University of Vienna, Vienna, Austria), Dr. Dave Ellis and Dr. Neil Verity (DURECT Corporation, Cupertino, CA), Dr. Alex Yang (Xelay Acumen, Belmont, CA), Dr. Sten Rasmussen (Orthopaedic Surgery Research Unit, Medical Education, Aalborg University Hospital, Aalborg, Denmark)

Presentation Title: Treatment of Postoperative Pain in Major Abdominal Surgery with SABER®-Bupivacaine: Results of the BESST Trial

Authors: Dr. Tong J. Gan (Department of Anesthesiology, Duke University School of Medicine, Durham, NC), Dr. Harry Papaconstantinou (Department of Surgery, Scott and White Memorial Hospital and Clinic, Temple, TX), Dr. Marcel Durieux (Department of Anesthesiology, University of Virginia Health System, Charlottesville, VA), Dr. Neil Singla (Lotus Clinical Research, Inc., Arcadia, CA), Dr. Samir Johna (Department of Surgery, Kaiser Permanente, Fontana, CA), Dr. Dmitri Lissin, Dr. Neil Verity and Dr. Dave Ellis (DURECT Corporation, Cupertino, CA), Dr. Harold Minkowitz (Department of Anesthesiology, Memorial Hermann City Medical Center, Houston, TX)

 

1


Presentation Title: Pharmacokinetic Characteristics of SABER®-Bupivacaine in Humans Demonstrate Sustained Drug Delivery for up to 72 Hours in a Variety of Surgical Models

Authors: Dr. Jaymin Shah, Dr. Dave Ellis, and Dr. Neil Verity (DURECT Corporation, Cupertino, CA)

About POSIDUR

POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER® technology to deliver bupivacaine to provide up to three days of pain relief after surgery. We are in discussions with potential partners regarding licensing development and commercialization rights to POSIDUR, for which we hold worldwide rights. In February 2014, DURECT received a Complete Response Letter from the FDA for its new drug application (NDA) for POSIDUR. Based on its review, the FDA has determined that they cannot approve the NDA in its present form, stating the NDA does not contain sufficient information to demonstrate that POSIDUR is safe when used in the manner described in the proposed label, and the FDA has indicated that additional clinical safety studies need to be conducted. DURECT is evaluating the issues described in the Complete Response Letter and plans to have further discussions with the FDA around them.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

DURECT Forward-Looking Statement

The statements in this press release regarding POSIDUR, the potential benefits and uses of POSIDUR, our discussions with potential partners regarding licensing development and commercialization rights for POSIDUR, and our interactions with the FDA regarding approval of the POSIDUR NDA are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk that we will not be able to consummate any licensing transactions for development and commercialization of POSIDUR, the risk of adverse decisions by the FDA or other regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by the FDA or regulatory agencies, the risk that we may not be able to adequately address all of FDA’s concerns regarding the POSIDUR NDA or there could be a delay in addressing such concerns, the potential that FDA may not grant regulatory approval of POSIDUR, the risk of potential adverse effects arising from additional testing or use of POSIDUR, and the potential that the data that we have generated or may generate may not be deemed sufficient by FDA or other regulatory agencies to support regulatory approval of POSIDUR. Further information regarding these and other risks is included in DURECT’s Form 10-K on February 28, 2014 under the heading “Risk Factors.”

 

2


NOTE: POSIDUR™, SABER®, TRANSDUR®, and ELADUR™ are trademarks of DURECT Corporation. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

 

SOURCE:    DURECT Corporation
CONTACT:    Matthew J. Hogan, Chief Financial Officer, DURECT 408-777-4936

 

3